索拉菲尼片联合经肝动脉化疗栓塞术治疗原发性肝癌的临床疗效

Clinical Efficacy of Sorafenib Tablets Combined with Transcatheter Arterial Chemoembolization in the Treatment of Primary Liver Cancer

目的:探讨索拉菲尼片联合经肝动脉化疗栓塞术(TACE)治疗不可手术切除的原发性肝癌的临床疗效及安全性。方法:选取2019年9月-2020年12月某院收治的62例不可手术切除肝癌患者为研究对象,按照均等单盲法将参与本研究的患者分为对照组和试验组各31例,对照组采用单纯TACE治疗,试验组在对照组的治疗上采用索拉菲尼片口服,统计两组治疗有效率以及药物不良反应的发生情况,并比较两组无疾病进展生存时间、总生存时间。结果:试验组的治疗有效率与疾病控制率分别为93.55%、96.77%,对照组治疗有效率与疾病控制率分别为70.97%、90.32%,试验组明显更高,差异显著(P<0.05);两组不良反应发生率对比无明显差异(P>0.05),试验组的无疾病进展生存时间、总生存时间均长于对照组,差异显著(P<0.05)。结论:对不可手术切除的原发性肝癌患者TACE术后辅助索拉菲尼片治疗,可有效提高疾病控制率与治疗有效率,提升生活质量,降低肝癌复发风险,安全性高,临床疗效显著。

Objective:To investigate the clinical efficacy and safety of sorafenib tablets combined with transcatheter arterial chemoembolization(TACE) in the treatment of unresectable primary liver cancer.Methods:62 patients with unresectable liver cancer treated in a hospital from September 2019 to December 2020 were selected as the research object,and divided into two groups according to the equal single blind method.The control group was treated with TACE alone,while the experimental group was treated with sorafenib orally based on the control group.The effective rate of treatment and the incidence of adverse drug reactions in the two groups were counted,and the disease progression-free survival time and overall survival time were also compared between the two groups.Results:The treatment effective rate and disease control rate of the experimental group were 93.55% and 96.77%,respectively,and those of the control group were 70.97% and 90.32%,respectively,which were significantly higher in the experimental group,with significant difference(P0.05).The progression free survival time and overall survival time of the experimental group were longer than those of the control group,with significant difference(P<0.05).Conclusion:Sorafenib adjuvant therapy can effectively improve the disease control rate and treatment efficiency,improve the quality of life,and reduce the risk of recurrence of liver cancer in patients with unresectable primary liver cancer after TACE,with high safety and significant curative effect.